Health Care • Biotechnology: Pharmaceutical Preparations
$10.75 ▲ +0.11
(+1.03%)
MKT CAP: $1.96B • VOL: 1.75M
52W L $5 52W H $11
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$9
MEDIAN
$12
MEAN
$12
HIGH
$15
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE XERS TAPE
XERS // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $13.01 | $12.36 | 2025-02-14 | $9.78 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $13.54 | $12.68 | 2025-02-06 | $10.10 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $12.25 | $11.83 | 2025-01-29 | $10.32 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $10.96 | — | 2025-01-17 | $10.54 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $9.46 | $10.21 | 2025-01-09 | $9.57 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $12.79 | $11.18 | 2024-12-18 | $9.35 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $10.43 | $10.86 | 2024-12-04 | $10.00 | -4.3% | 48% | C |